Gastrointestinal disorders ( mild-to-moderate nausea and vomiting) were the most common adverse events, as it was seen in 45 patients (80%) in the liraglutide group and 14 patients (54%) in the placebo group Table 3
But to do that, we need lower prices, thoughtful coverage policies, and a clearer understanding of who benefits most. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults was published in JAMA Health Forum in March 2025
SLIMMER Phase 3 (ecnoglutide, 40 weeks): Key characteristics: Lowest discontinuation rate among the drugs compared here (~2%) GI events described as "mild-to-moderate" with no detailed breakdown of individual symptom rates publicly available The biased agonism profile may contribute to reduced severity of GI effects Discontinuation rates of 6-11% across dose groups (including all causes, not just AEs) Demonstrates that cAMP bias may translate to a clinically meaningful tolerability advantage CT-388# CT-388 is a signal-biased dual GLP-1/GIP receptor agonist developed by Roche/Genentech
When should I see a doctor about hair loss while taking a GLP-1
If your hair density does not return after your weight has stabilized, the temporary stress may have accelerated a permanent condition
Diabetes Spectrum 2006
